Skip to NavigationSkip to content

Lundbeck and Otsuka to collaborate in CNS

Published on 11/11/11 at 03:58pm

Lundbeck and Otsuka have signed a major collaborative deal to sell and develop up to five CNS drugs, including a new formulation of antipsychotic Abilify.

Otsuka will receive up to $1.4 billion in total from Lundbeck in upfront payment and development and regulatory milestone payments.

Lundbeck will pay up to $1.8 billion to Otsuka, which also includes sales milestones, and both companies will share the sales as well as development and marketing costs.

Among the five treatments include an injectable depot formulation of Otsuka’s atypical antipsychotic Abilify (aripiprazole).

The drug was first approved by the FDA in 2004 and is licensed to treat schizophrenia and bipolar disorder, and is co-marketed with Bristol-Myers Squibb in the US. 

The Japanese firm made 3.7 billion Yen ($478 million) from its share of the drug last year.

A once-monthly depot formulation would help ensure patients are receiving their medication correctly, and would allow Abilify to compete with other atypical antipsychotics in depot form,

The firm is expected to submit the depot formulation to the FDA early next year and in Europe during 2013.  Under the terms of the deal Lundbeck will receive half of all sales in Europe and 20% in the US for the new formulation.

In the pipeline is Otsuka’s schizophrenia and manic-depressive disorder candidate OPC-34712 (currently in Phase III) and up to three innovative earlier stage projects from Lundbeck.

For OPC-34712, Lundbeck gains rights to half of all sales in Europe and Canada and 45% in the US.

Dr Taro Iwamoto, president and representative director of Otsuka, said: “Lundbeck’s expertise in developing depression and anxiety treatments and Otsuka’s expertise in developing anti-psychotics will maximise the medical and commercial value of Otsuka’s portfolio in CNS.

“In addition, our partnership with Lundbeck will enable us to establish a strong platform to deliver these compounds to patients who need them in Europe, South America, Oceania, the BRIC countries and other countries around the world.”

Lundbeck said the deal ‘significantly enhances’ its long-term growth prospects and even though it would see increased commercialisation and R&D costs in 2012-14, it said the firm’s long term profits forecast would not be affected.

Ben Adams

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches